Clinical Trial Update: Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple-dose regimens of CHF 5074 in subjects with mild cognitive impairment and potential progression to Alzheimer's disease was with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• CHF 5074

Snippet

Sponsor: CERESPIR | Conditions: Alzheimer's Disease | Phase 2 | Status: WITHDRAWN